Treatment of mice with recombinant ANXA1 reduces liver inflammation and fibrosis without affecting steatosis and metabolism (50), suggesting a possible mechanism by which Lal−/− mice attempt to combat liver inflammation. Here, LIPA is linked to steatosis.